Scientific advice on how long to take donepezil (Aricept) before you need to stop taking it and rest

Donepezil is a reversible acetylcholinesterase inhibitor mainly used to improve cognitive function in patients with mild to moderate Alzheimer’s disease (AD). By inhibiting the breakdown of acetylcholine, it can increase acetylcholine concentration in the brain, thereby improving memory, attention and executive functions. Since its function is to continuously increase the level of neurotransmitters, donepezil usually needs to be taken regularly for a long time to maintain its efficacy. However, in actual clinical practice, whether the drug needs to be discontinued or "withdrawal", as well as the time and period of discontinuation, need to be scientifically evaluated based on the individual patient's condition.

Generally speaking, donepezil does not require fixed periodic discontinuation in clinical application. Most guidelines recommend that patients should continue long-term use to maintain cognitive function and activities of daily living. The therapeutic effect usually begins to appear after 4 to 6 weeks of continuous medication, and the best effect generally requires 3 to 6 months of continuous medication observation. During this period, cognition, activities of daily living, and medication tolerance should be assessed regularly. If a patient experiences severe side effects, such as significant gastrointestinal discomfort, abnormal heart rhythm, or significant weight loss, the doctor may consider temporarily reducing the dose or discontinuing the drug to reduce risk.

For patients who have been taking medication for a long time, occasional "drug discontinuation evaluation" is mainly used to determine whether the drug effect is still obvious or whether drug resistance exists. Short-term observation can usually be carried out under the guidance of a doctor, such as dose reduction or short-term drug withdrawal for 1 to 2 weeks, while cognitive function and behavioral status are closely monitored. If significant cognitive decline or symptom aggravation occurs, the original dose should be resumed immediately. In most cases, discontinuation of donepezil may result in symptom rebound or accelerated cognitive decline, so long-term voluntary discontinuation or frequent "drug holidays" are not recommended.

In general, the administration strategy of donepezil should be based on the principle of continuous stability, and the efficacy and safety should be evaluated through regular follow-up. Unless there are intolerable adverse reactions or special clinical needs, there is no need to discontinue the drug at fixed intervals. Patients and their families should maintain close communication with their doctors and develop individualized medication plans based on cognitive assessment results, life functions and tolerance. Scientific management of the medication cycle and observation of efficacy can help achieve long-term clinical benefits of donepezil while ensuring safety.

Reference link:https://www.drugs.com